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Summary 
Objective 
To assess the pain and functional disability levels corresponding to an indication for total joint 
replacement (TJR) in hip and knee osteoarthritis (OA). 
Methods 
Design: International cross-sectional study in 10 countries. Patients: Consecutive outpatients with 
definite hip or knee OA attending an orthopaedic outpatient clinic. Gold standard measure for 
recommendation for TJR: Surgeon’s decision that TJR is justified. Outcome measures: Pain (ICOAP: 
intermittent and constant osteoarthritis pain, 0–100) and functional impairment (HOOS-PS/KOOS-PS: 
Hip/Knee injury and Osteoarthritis Outcome Score Physical function Short-form, 0–100). Analyses: 
Comparison of patients with vs without surgeons’ indication for TJR. Receiver Operating 
Characteristic (ROC) curve analyses and logistic regression were applied to determine cut points of 
pain and disability defining recommendation for TJR. 
Results 
In all, 1909 patients were included (1130 knee/779 hip OA). Mean age was 66.4 [standard deviation 
(SD) 10.9] years, 58.1% were women; 628/1130 (55.6%) knee OA and 574/779 (73.7%) hip OA 
patients were recommended for TJR. Although patients recommended for TJR (yes vs no) had worse 
symptom levels [pain, 55.5 (95% confidence interval 54.2, 56.8) vs. 44.9 (43.2, 46.6), and functional 
impairment, 59.8 (58.7, 60.9) vs. 50.9 (49.3, 52.4), respectively, both P < 0.0001], there was 
substantial overlap in symptom levels between groups, even when adjusting for radiographic joint 
status. Thus, it was not possible to determine cut points for pain and function defining 
‘requirement for TJR’. 
Conclusion 
Although symptom levels were higher in patients recommended for TJR, pain and functional 
disability alone did not discriminate between those who were and were not considered to need TJR 
by the orthopaedic surgeon. 
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Introduction 
Osteoarthritis (OA) is a major cause of disability worldwide1. Over the past years, interest has grown 
among the scientific community, pharmaceutical companies, and regulatory agencies in the 
development of drugs that might influence the natural history of structural changes in OA by 
preventing, retarding, or reversing cartilage breakdown. Interest exists, therefore, in identifying a 
valid, dichotomous outcome variable that reflects the natural history of structural changes in OA. In 
particular, interest has grown in using the requirement of total joint replacement (TJR) as a “hard” 
endpoint [2] and [3]. Limitations exist, however, in the use of such an outcome. Performance of TJR is 
a measure of utilization and not of a health state. Numerous non-health related factors have been 
shown to influence utilization including patient race, ethnicity, income, activity level and preferences 
among others, and other non-musculoskeletal health factors influence the decision to undergo TJR 
including comorbidity [2], [3], [4], [5], [6], [7], [8], [9] and [10]. Thus, a better alternative might be to 
change “time to TJR” to “time to fulfill the criteria for TJR”11. In this context and as described 
elsewhere [12] and [13], an international working group was created under the auspices of 
Osteoarthritis Research Society International (OARSI) and Outcome Measures in Rheumatology 
Clinical Trials (OMERACT). The group’s charge was to elaborate a set of criteria defining a state 
corresponding to recommendation for TJR in patients with symptomatic knee and hip OA, for use in 
clinical trials evaluating potential disease-modifying drugs and other interventions in OA. It was 
decided that the domains of pain, physical function and joint structure on radiographs [14], 
[15] and [16] would be combined as a surrogate measure of outcome. The consensus was to consider 
the level of symptoms (i.e., pain and function) at one point, and a definition of radiological 
progression between two time-points16. The final binary outcome could then be used as a definition 
for “responders/non-responders” in OA clinical trials. For each of these domains, a categorical 
outcome needs to be used to render combination of the domains feasible. To this end, it is necessary 
to categorize or dichotomize the continuous variables pain and functional disability. 
Thus, the objective of the present study was to define cut points for both pain and functional 
disability, leading to a joint replacement indication. To this end, a data-driven approach, based on 
real patient data, was chosen. 
This article presents the results of a large cross-sectional study performed to define cut-point levels 
for pain and functional disability among patients with hip or knee OA being evaluated by orthopaedic 
surgeons for possible need of TJR. The goal was to use these cut-offs to develop a theoretical 
indication for TJR, in hip and knee OA. 
Patients and methods 
Study design 
This international prospective observational cross-sectional study was conducted in the orthopaedics 
departments of tertiary-care and secondary-care centers in Europe (12 centers, one per country in 
the Czech Republic, Italy, Spain, Sweden, and the United Kingdom; two per country in France and The 
Netherlands; three in Germany), Canada (two centers), the United States of America (two centers), 
and Australia (two centers). 
Ethical approval was obtained from all participating centers. 
Study population 
Consecutive outpatients consulting with an orthopaedic surgeon in one of the participating centers 
and with a diagnosis of hip or knee OA (according to the orthopaedic surgeon and based on 
symptoms and radiographs) were included. Only patients for whom the surgeon answered ‘There 
are definite radiographic signs of OA of the target joint’ were included. Exclusion criteria were: no 
definite diagnosis of OA, prior TJR or prior osteotomy of the target joint, concomitant inflammatory 
arthritis (e.g., rheumatoid arthritis, spondyloarthropathy), patient inability to fill in a questionnaire or 
patient refusal. 
Gold standard: indication for TJR 
The gold standard was defined by the orthopaedic surgeon’s opinion regarding the 
recommendation for TJR, operationalized as the surgeon stating that (1) TJR was recommended for 
the patient or (2) the patient’s pain and functional disability were severe enough to indicate TJR 
but surgery was not indicated because of comorbidity or patient declining surgery. These answers 
defined an ‘indication for TJR’, irrespective of whether the joint replacement surgery was 
performed or not. 
Pain and functional disability 
Two self-reported measures, pain and functional disability, were collected using the intermittent and 
constant osteoarthritis pain (ICOAP) score [17] and [18] for pain, and the Hip disability and 
Osteoarthritis Outcome Score (HOOS) for hip, and Knee injury and Osteoarthritis Outcome Score 
(KOOS) for knee for function [19], [20] and [21]. All scores had Likert answer modalities. The scores 
were linearly transformed to 0–100 scores, where higher scores indicate worse status. These 
questionnaires previously underwent translation and cross-cultural adaptation into each of the 
participating countries’ languages18. 
Clinical severity was also estimated through the pain, stiffness, and function subscales of the 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)22 with Likert answer 
modalities. Results were also linearly transformed to a 0–100 score where higher scores indicate 
worse status. 
Symptom duration 
The duration of symptoms, at their current level, was collected by self-report. 
Radiographic severity 
The local investigator evaluated the radiographs of the target joint, recording joint space narrowing 
as categories (none, <25%, 25–50%, 50–75%, >75%). Not all canters participated in the radiographic 
evaluation of severity. 
Other clinical data collection 
Demographic data included age, and sex. Other information included weight and height (body mass 
index was then calculated), and date of onset of development of OA symptoms in the target joint. 
Statistical analysis 
1. Sample size: It was anticipated that 1000 knee OA and 1000 hip OA patients would be included, 
allowing the assessment of Receiver Operating Characteristic (ROC) curves and areas under the curve 
(AUCs) with a precision of 0.03 for an expected AUC of 0.8023. Other sample size calculations based 
on expected sensitivities or specificities, led to smaller sample sizes (data not shown). 
2. Descriptive analysis of pain and functional disability: The distributions of the two variables were 
analysed for both hip and knee OA, according to the gold standard outcome (recommendation for 
TJR yes/no) and compared using Student’s t test or the Wilcoxon rank test. Pain and function were 
also categorized in deciles, and the frequency of the positive gold standard was assessed (with exact 
confidence intervals, by the Clopper–Pearson method24) to describe the relation between pain, 
function and indication for TJR. 
3. Univariate ROC curves: This was the main planned analysis to assess cut points for pain and 
functional disability. The ability of pain and functional disability to predict the gold standard was 
assessed in a univariate manner by a non-parametric ROC curve25 and its AUC was calculated. The 
null hypothesis was that pain and functional disability levels could not distinguish the groups 
’recommended for TJR yes/no’. The criteria for accepting the null hypothesis were AUCs <0.65. If 
the null hypothesis was rejected, it was planned to assess cut points to maximise specificity (for a 
specificity of 90%, 95%, 98%) but also sensitivity, and for each cut point, the sensitivity, the 
specificity, and the likelihood ratios were assessed. 
To take into account radiographic severity, the analyses were stratified on radiographic severity by 
analysing the relationship between symptoms and recommendation for TJR, for a radiographic joint 
space narrowing <50%, 50–75%, and more than 75% separately. 
4. Correlation between pain and function was examined graphically and tested by Spearman’s 
correlation coefficient. 
5. Logistic regression: Pain and function were combined based on logistic regression. In the logistic 
regression, pain and function were entered into a bivariate model to predict theoretical indication 
for TJR, with a stepwise selection mode. The goodness-of-fit was checked with Hosmer–
Lemeshow’s test26. The regression parameters of the variables pain and function allowed the 
assessment of the relative importance (weight) of these variables vs the gold standard, thus allowing 
us to combine the two domains (β1pain + β2function where β1 and β2 are the regression 
parameters of the variables pain and function respectively). The combination was then tested using 
non-parametric ROC curves as described above, and stratified on radiographic severity as explained 
above. 
6. Additional sensitivity analyses: Analyses were run separately for the hip and knee. Potential 
heterogeneity across centers (regrouped by country) was assessed. A modified version of the gold 
standard question was modelled (‘surgeon saying the patient is referred for TJR’, not taking into 
account patients not referred to surgery due to comorbidities or patient refusal). Another statistical 
technique involving the 75th percentile of the distribution of patients recommended for TJR was 
applied. The 75th percentile gave the value of the sum (pain + function) defining 75% of the 
population which had an indication for TJR. Furthermore, the same analyses were performed using 
WOMAC pain and function subscales. Finally, a sensitivity analysis was performed, excluding patients 
from the United Kingdom since for these patients, the questionnaires had been administered 
differently. 
All analyses were performed using the Statistical Analysis System (SAS), version 9.1. Statistical 
significance was set at 0.05. 
Results 
Patient characteristics (Table I) 
In all, 1974 patients were included; 1909 had an answer for the gold standard question and were 
analysed: 1130 knee OA and 779 hip OA patients (Table I). The patients were included in Europe 
(N = 1050), Australia (N = 394), the United States of America (N = 261), and Canada (N = 204). 
Supplementary file 1 shows the characteristics of the patients from the different centers. 
Table I. Patients’ characteristics 
 
All patients 
N = 1909 
Knee patients 
N = 1130 
Hip patients 
N = 779 
Age, years 66.4 ± 10.9 67.5 ± 10.4 64.9 ± 11.4 
 All patients 
N = 1909 
Knee patients 
N = 1130 
Hip patients 
N = 779 
Sex, N (%) women 1086 (58.1) 657 (58.9) 429 (56.9) 
OA symptom duration, years 5.4 ± 6.9 6.3 ± 7.7 4.1 ± 5.5 
Body mass index, kg/m2 29.9 ± 6.3 31.0 ± 6.8 28.3 ± 5.2 
Pain, ICOAP score 51.6 ± 22.3 50.3 ± 22.0 53.3 ± 22.6 
Functional disability, HOOS-
PS/KOOS-PS scores 
56.5 ± 20.0 55.5 ± 18.8 57.8 ± 21.5 
Pain, WOMAC subscale 54.0 ± 21.0 52.5 ± 20.8 56.3 ± 21.1 
Function, WOMAC subscale 57.0 ± 20.5 55.2 ± 20.2 59.5 ± 20.8 
Radiographic joint space narrowing, N (%)* 
 <25% 95 (10.7) 67 (13.0) 28 (7.8) 
 25–50% 131 (14.7) 95 (18.5) 36 (9.6) 
 50–75% 274 (30.8) 159 (31.0) 115 (30.6) 
 >75% 389 (43.8) 192 (37.4) 197 (52.4) 
Results are presented as mean ± SD unless otherwise mentioned. Pain and functional disability were 
linearly transformed to 0–100 scores where 100 = worst state. 
∗ 
X-ray scoring was only available for 889 patients and % are % of available data. 
Full-size table 
Mean age of the patients was 66.4 [standard deviation (SD): 10.9] years, 58.1% were women, mean 
OA duration was reported as 5.4 (SD 6.9) years. Of the 1909 patients, 628 (55.6%) knee patients and 
574 (73.7%) hip patients were recommended for TJR. The recommendation was mainly related to the 
surgeon stating TJR was indicated (91.7% of indications) and much less often to the answers 
‘although the symptoms are severe enough, the patient declined surgery’ (4.0%) or ‘there were 
comorbidities’ (4.3%). The frequency of indication for TJR varied across countries, from 33.8% with 
an indication for surgery among the patients from the Italian center, to 87.9% among the patients 
from the Czech Republic center. 
Pain assessed by ICOAP and functional disability by HOOS-PS/KOOS-PS (Table II) 
Scores for pain and functional disability were not normally distributed (Fig. 1 for online version only), 
but showed a wide spread in severity of symptoms. Pain had the following distribution in knee OA: 
mean ± SD 50.3 ± 22.0, median 50.0 (first quartile = 31.8, third quartile = 68.2, range 0–100) and in 
hip OA: mean ± SD 53.3 ± 22.6, median 54.5 (first quartile = 4.1, third quartile = 70.5, range 0–
100). Functional impairment had the following distribution in knee OA: mean ± SD 55.5 ± 18.8, 
median 51.2 (first quartile = 42.0, third quartile = 66.6, range 0–100) and in hip OA: mean ± SD 
57.8 ± 21.5, median 55.9 (first quartile = 41.7, third quartile = 74.8, range 0–100). 
Table II. Symptom levels and radiographic severity according to recommendation for TJR 
 
Knee OA: 
TJR+N = 628 
Knee OA: 
TJR−N = 502 
Hip OA: 
TJR+N = 574 
Hip OA: 
TJR−N = 205 
Pain, ICOAP score 53.7 (52.0, 55.5) 45.9 (44.0, 47.9) 
57.3 (55.6, 
59.1) 
42.4 (39.1, 
45.7) 
Functional disability, 
HOOS-PS/KOOS-PS scores 
58.1 (56.6, 59.7) 52.3 (50.5, 54.0) 
61.4 (59.8, 
63.1) 
47.4 (44.1, 
50.7) 
Pain, WOMAC subscale 56.4 (54.8, 57.9) 47.3 (45.3, 49.4) 
59.8 (58.3, 
61.4) 
45.9 (42.4, 
49.3) 
Function, WOMAC subscale 59.0 (57.4, 60.5) 50.3 (48.3, 52.4) 
63.3 (61.7, 
64.9) 
48.7 (45.3, 
52.2) 
Duration of symptoms at 
the current level, months 
11.0 (6.2,15.2) 5.9 (2.3, 10.2) 6.9 (3.5, 11.5) 5.9 (2.1, 10.6) 
Radiographic joint space narrowing, N (%)* 
 <25% 3 (1.2) 64 (23.6) 3 (1.1) 25 (22.3) 
 25–50% 24 (10.0) 70 (25.8) 14 (5.3) 22 (19.6) 
 50–75% 85 (35.4) 74 (27.3) 75 (28.5) 39 (34.8) 
 >75% 128 (53.3) 63 (32.3) 171 (65.0) 26 (23.2) 
Results are presented as mean (95% confidence interval) except for radiographic results. Pain and 
functional disability were linearly transformed to 0–100 scores where 100 = worst state. TJR+: 
indication for TJR. TJR−: no indication for TJR. For other abbreviations please see Table I. 
∗ 
% of available data. 
Full-size table 
Pain and functional disability levels and their duration, for those who did vs did not receive a TJR 
recommendation, are shown in Table II. Patients meeting the gold standard had higher symptom 
levels. For knee/hip patients pooled, mean pain was 55.5 [95% confidence interval 54.2, 56.8] for 
those with TJR recommendation vs 44.9 [43.2, 46.6] for those without TJR recommendation 
(P < 0.0001). Mean functional impairment was 59.8 [58.7, 60.9] for those with TJR recommendation 
vs 50.9 [49.3, 52.4], for those without TJR recommendation (P < 0.0001). However, there was a wide 
overlap in symptom levels between groups: almost 50% of patients in the lowest decile of symptom 
scores were considered candidates for TJR, whereas only 75% of patients in the highest decile were 
considered candidates (Fig. 2 for online version only). 
Symptom duration 
The duration of symptoms at their current level was longer for patients who did vs those who did not 
receive a TJR recommendation (Table II). 
Univariate ROC curves 
Taking pain and function separately, in the pooled hip/knee population, it was not possible to 
determine relevant cut points defining recommendation for TJR (Fig. 1). The AUCs for the ROC curves 
for pain and function vs the gold standard were 0.64 [95% confidence interval, 0.61, 0.67] and 0.63 
[0.60, 0.66], respectively. Thus, we had to accept the null hypothesis (i.e., that pain and functional 
disability levels do not distinguish patients with vs without a recommendation for TJR). The cut points 
had low diagnostic properties: e.g., for a specificity of 0.90, the sensitivity was only 0.23 for pain and 
0.24 for function; i.e., the positive and negative likelihood ratios were only (1.17; 0.43) for pain and 
(1.18; 0.42) for physical disability. 
 
Fig. 1. Ability of pain and functional impairment severity to predict indication for TJR in 1909 hip or 
knee OA patients. (a) pain, AUC for curve: 0.64 (95% confidence interval, 0.61–0.67), (b) functional 
disability, AUC for curve: 0.63 (95% confidence interval, 0.60–0.66). 
View thumbnail images  
View high quality image (281K) 
After stratifying on radiographic severity, the AUCs were not much improved (AUCs ranging from 
0.65 to 0.68 for pain, and 0.60 to 0.63 for function, respectively) and cut points assessed had low 
diagnostic properties (data not shown). 
Correlation and relative importance of pain, functional disability and radiographic status 
Pain and functional disability were only moderately correlated (R = 0.59, P < 0.0001), in the pooled 
hip/knee population, indicating that these domains were not redundant. 
In logistic regression, the coefficients of regression of pain and function were very similar (and 
significant), indicating pain and function are independent predictors of recommendation for TJR, with 
similar weights. The coefficients of regression were 0.015 for pain, and 0.013 for function, 
respectively (both P < 0.0001). This result justified our combining pain and functional status 
additively with equal weights. Furthermore, radiographic severity was a significant independent 
predictor of recommendation for TJR (P < 0.0001) in the pooled hip/knee population. 
ROC curves for the sum (pain + function) 
With the sum (pain + function), it was also not possible to determine cut points leading to relevant 
sensitivity/specificity in the pooled hip/knee population: the AUC of the ROC curve was 0.64 [95% 
confidence interval, 0.61, 0.67], and for a specificity of 0.90 the sensitivity was 0.27 (i.e., positive and 
negative likelihood ratios were 2.70; 0.81). 
When these analyses were stratified on radiographic severity, the AUCs were not improved (AUCs 
ranging from 0.62 to 0.65 in the different radiographic groups). 
Sensitivity analyses 
Several sensitivity analyses including use of alternate measures, specifically the WOMAC pain and 
function subscales (Supplementary file 2); and changing the gold standard to true indication for TJR 
(i.e., not considering patients with severe status but comorbidities or patient refusal as 
recommendations for TJR), did not modify the results (data not shown). 
The 75th percentile technique gave 89 as the value of the sum (pain + function) defining 75% of the 
population which had an indication for TJR (respectively, 87 and 92, for knee and hip). When applying 
the cut point of 89 to the whole population, 59% of the patients were above that level; specificity 
was 0.51, sensitivity was 0.66, the positive and negative likelihood ratios were (1.34; 0.86). 
Excluding patients from the United Kingdom did not modify the conclusions (data not shown). 
However, analysing the participants with hip or knee OA separately, the association between 
symptoms and surgery was stronger in the hip than in the knee (Fig. 2). 
 Fig. 2. Ability of the sum (pain + function) to predict indication for TJR, in knee and hip OA separately 
(a) Knee, AUC for the ROC curve: 0.60 (95% confidence interval, 0.56–0.64) (b) Hip, AUC for the ROC 
curve: 0.70 (95% CI, 0.66–0.75). 
View thumbnail images  
View high quality image (305K) 
The AUCs of the ROC curves of the sum pain + function were higher in hip OA [AUC, 0.70, 95% 
confidence interval (CI), 0.66–0.75] than in knee OA (AUC, 0.60, 95% CI, 0.56–0.64). However, even 
so, for hip patients the cut points assessed had low diagnostic properties; e.g., the cut point leading 
to a specificity of 90% was 66 (sum pain + function); for that cut point, for a specificity of 0.92, the 
sensitivity was only 0.31; i.e., the positive and negative likelihood ratios were only (1.35; 0.23). 
We also showed when analysing the centers separately (regrouped by country), that in certain 
centers pain and function were more strongly related to receipt of a TJR recommendation than in 
other centers (e.g., AUC of the ROC curves for the sum pain + function in hip OA, 0.75–0.86 in centers 
in Canada, France, Germany and Australia as compared with 0.54–0.67 in centers in The United 
Kingdom, the United States, the Netherlands and the Czech Republic, Supplementary file 3). 
Discussion 
This large-scale international study was launched to determine whether self-reported measures of 
pain and function could be used to accurately identify patients with OA whose surgeons 
recommended them for total hip or knee arthroplasty. The first conclusion of this work is that, 
indeed, among patients with hip and knee OA referred to an orthopaedic surgeon, the level of 
symptoms was higher among patients for whom TJR was indicated by the orthopaedic surgeon. Both 
the level of pain and self-reported functional impairment were independently, though weakly, 
predictive of the surgeon’s recommendation for TJR. The second conclusion is that we could not 
find a cut point for pain and or physical disability that accurately discriminated across different 
countries, patients who did vs did not receive a TJR recommendation, as the AUCs for ROC curves 
were low (<0.65). Radiographic severity, when available, was a strong predictor of recommendation 
for TJR but stratifying by radiographic joint status did not modify our conclusions. 
Factors consistently predicting TJR are symptom levels and radiographic severity. Less consistent 
predictors have included gender, age and current treatment [2], [4], [5], [6], [7], [8] and [9]. In the 
present study, the mean values of pain and function in the group of patients considered candidates 
for surgery by the surgeons were consistent with previously reported data in this area [27], [28], [29], 
[30], [31] and [32]. We confirmed here that both pain and functional disability are independent 
predictors of recommendation by a surgeon for TJR; however, previous studies did not include a 
control group to attempt to determine cut points for patient-reported outcomes. In this study, using 
the ICOAP and HOOS-PS/KOOS-PS, though pain and function were correlated (as could be expected), 
the correlation was only moderate, which indicates that pain and function using these scores are not 
redundant when analysing OA patients. Furthermore, we also found that the duration of the 
symptoms at their current level was an important factor explaining indication for TJR. Other 
predictors included radiographic severity, stiffness (assessed by WOMAC) and OA disease duration 
(data not shown). 
Despite the fact there was a difference in the level of symptoms between the two groups (candidate 
for surgery yes/no) the overlap between the two groups prevented us from proposing a specific cut-
off. Indeed, among these OA patients referred to an orthopaedic surgeon, most patients were 
symptomatic. However, the surgeons often decided that surgery was warranted even among the less 
symptomatic patients (around 50% of the patients in the lower decile of symptoms were 
recommended for TJR, Fig. 2 online), or that surgery was not warranted even if the symptoms were 
severe (only around 75% of these patients were considered surgery candidates). This indicates that 
the level of symptoms in this population was not the only driver for such a TJR indication [30], 
[31] and [32]. Possibly, the surgeons paid greater attention to the radiographic severity than to the 
symptom levels [10], [27] and [33] and several studies have indicated a discordance between 
radiographs and symptoms in lower-limb OA [27], [34], [35], [36] and [37]. In the present study 
however, stratifying the analyses on radiographic severity did not modify our conclusions. Finally, the 
present results indicated a stronger relationship between symptoms and surgical indication in hip OA 
than in knee OA. 
It is possible that the questionnaires used, the ICOAP and KOOS-PS/HOOS-PS [17], [18], [19], 
[20] and [21] (which were not seen by the orthopaedic surgeon) may assess different aspects of 
symptoms, than what the orthopaedic surgeon usually assesses in the clinic; however, it is reassuring 
to note that these new tools gave results very similar to the WOMAC subscales. Indeed, the 
sensitivity analyses performed using WOMAC data confirmed our main results. Perhaps also, other 
data related to patient-reported outcomes could be relevant in the indication for TJR, such as 
worsening of symptoms (e.g., minimal clinically important deterioration); however, we did not collect 
change in status in this study, but only status at one time point, and persistence of that status, since 
we felt that a decision for TJR would be more strongly based on status than on change. Clearly, in 
addition to symptomatic severity, many other factors are as strong or stronger determinants of 
surgery [9], [38], [39], [40] and [41]. Furthermore, perhaps other aspects of symptomatic severity are 
taken into account in the surgeons’ decision, e.g., the duration of symptoms (whereas 
questionnaires have a short time-frame), or the ongoing symptomatic treatment of the patient that 
may influence his/her current level of symptoms4. Finally, the surgeons may have based their 
surgical decision on joint mobility or peri-articular amyotrophy38, which were not assessed here. 
There were clear differences across centers and countries; these might be explained by several 
elements, including differences in the health care systems, or characteristics/training of the 
surgeons. In all, the current study confirms the wide variability in the indication for TJR suggested by 
studies of who actually receives a TJR; these results provide evidence that variability in surgeons’ 
recommendations and practices is an important contributor to the clinical variability among TJR 
recipients. 
This study has strengths and weaknesses. It is a large, international study which enhances the 
external validity of our results. On the other hand and as could be expected, there were differences 
across centers and countries in terms of symptomatic severity and in terms of the frequency of 
indication for TJR as assessed by the orthopaedic surgeon [9] and [32]. We do not believe this is an 
important limitation to the present results. Indeed, the objective here was to develop international 
criteria reflecting a level of OA symptoms and disability at which point TJR should be considered, for 
use as outcome measure in clinical trials. In this context, it was necessary to include patients from 
different backgrounds. In this study, one possible bias is that only symptomatic OA patients were 
included since the patients had to have definite OA to be included, and were in fact seeing an 
orthopaedic surgeon, generally to discuss a surgical indication for their target joint (we do not have 
information regarding if the patients were coming for the first time, or for return visits). Therefore 
the present study did not include many asymptomatic patients which may explain the low predictive 
power of symptomatic severity here. Indeed, symptom thresholds associated with TJR in a more 
heterogeneous sample (including asymptomatic patients) might be relevant for defining endpoints 
for observational studies. Nevertheless, the patients in the study presented with a wide range of 
symptomatic severity, and only about half of them were considered candidates for TJR. Several 
statistical techniques and sensitivity analyses were performed, to further confirm the internal validity 
of our results; and the study was not underpowered. 
In this study, the gold standard was the surgeon’s opinion regarding need for TJR [13] and [28]. We 
considered that if surgery was recommended or if the surgeon considered symptoms were severe 
enough for surgery (although because of comorbidity10 or patient refusal9, the patient was not 
referred for surgery), a state of indication for TJR was attained. However, we did not collect data 
regarding actual carrying-out of surgery in these patients, which may differ widely [2], [3], [4], [5], 
[6], [7], [8], [9] and [10]. 
In conclusion, this large study indicates that among patients referred to an orthopaedic surgeon to 
discuss TJR, the level of symptoms was higher among patients for whom TJR was indicated by the 
surgeon, but there was no cut point for pain and functional disability allowing to discriminate 
between patients with or without an indication for TJR. 
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